THRV-1268 / Thryv Therap - LARVOL DELTA

Wave II: Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) (clinicaltrials.gov) - P2/3 | N=64 | Recruiting | Sponsor: Thryv Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • KCNH2

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Thryv Therapeutics, Inc. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Heart Failure • Obesity

Wave II: Phase 2/3 Study of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) (clinicaltrials.gov) - P2/3 | N=64 | Not yet recruiting | Sponsor: Thryv Therapeutics, Inc.

New P2/3 trial • Cardiovascular

The serum and glucocorticoid regulated kinase 1 (SGK1) inhibitor THRV-1268 attenuates hallmarks of heart failure by reducing inflammation and fibrosis beyond sodium/glucose cotransporter 2 inhibition (AHA 2025) - "BackgroundHeart failure (HF) remains a leading cause of morbidity and mortality despite current therapies. In contrast, treatment with EMPA or dapagliflozin did not attenuate TGFb-induced fibrosis.Conclusion1268 was superior to empagliflozin in mitigating HFrEF by reversing major hallmarks and biomarkers associated with HF. This analysis identified the direct impact of 1268 on cardiac fibroblasts as a potential differentiating mechanism from lesser effects seen with EMPA."

Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation

THRV-1268, a potent and selective serum and glucocorticoid regulated kinase (SGK1) inhibitor, improves adverse cardiac remodeling better than Jardiance® (empagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure (AHA 2025) - "THRV-1268 demonstrated superior cardioprotective effects compared to EMPA and in combination with EMPA in the TAC-model of HF. These data support continued development of THRV-1268 as a single or additive therapeutic approach for the optimal management of HF."

Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Thryv Therapeutics, Inc.

New P1 trial • Cardiovascular • Heart Failure • Obesity

THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure. (ESC-WCC 2025) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Thryv Therapeutics, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Apr 2025 ➔ Nov 2024 | Trial primary completion date: Apr 2025 ➔ Nov 2024

Trial completion • Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 (clinicaltrials.gov) - P1 | N=74 | Active, not recruiting | Sponsor: Thryv Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Atrial Fibrillation • Cardiovascular

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: Thryv Therapeutics, Inc.

New P1 trial • Atrial Fibrillation • Cardiovascular